Author

John C. Bell

Ottawa Hospital Research Institute

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

Brian Dennis LichtyiD· 1 shared Christopher L. BakeriD· 1 shared Christopher M. SilvestriiD· 1 shared Claire G. Morris· 1 shared Dennis McGonagleiD· 1 shared Derek T. CummingsiD· 1 shared Elizabeth Ann RoundhilliD· 1 shared Fiona Errington‐MaisiD· 1 shared

Activity by Year

2024-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

Brian Dennis LichtyORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Oncolytic Maraba virus MG1 mediates direct and natural killer cell-dependent lysis of Ewing sarcoma

Tyler Barr, Victoria A. Jennings, Elizabeth Ann Roundhill, Richard T. Baugh, Maisa Yamrali, Heather Elizabeth Owston, Dennis McGonagle, Peter Vasilios Giannoudis, Natasha J. Caplen, Javed Iqbal Khan, John C. Bell, Susan Ann Burchill, Fiona Errington‐Mais, Graham P. Cook

This study shows that the oncolytic Maraba virus MG1 can directly kill Ewing sarcoma cells and enhance NK cell-mediated cytotoxicity against them.

Cancers · Oct 14, 2025Peer-reviewedCancer Biology

Boosting of CAR-T cells with rhabdovirus is limited by type I interferon and rapid contraction

Rebecca Burchett, Claire G. Morris, Mira Ishak, Derek T. Cummings, Christopher L. Baker, Ricardo M. Marius, Natasha Kazdhan, Christopher M. Silvestri, John C. Bell, Brian Dennis Lichty, Scott R. Walsh, Yonghong Wan, Joanne A. Hammill, Jonathan L. Bramson

This study shows that boosting CAR-T cells with a VSV vaccine encoding the CAR-target leads to robust expansion but rapid contraction, while TCR-mediated boosting improves persistence and tumor eradication.

bioRxiv · Nov 29, 2024 · PreprintImmunology